Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 8:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–28 of 4 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Dedifferentiated Liposarcoma Clear all

Completed Phase 2Phase 3 Interventional Results available

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

NCT05218499

View directory record Official record

Conditions: Liposarcoma, Dedifferentiated
Interventions: Brigimadlin, Doxorubicin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older

Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 16 more

Source: ClinicalTrials.gov public record

Updated Mar 1, 2026 · Synced May 21, 2026, 8:09 PM EDT

Completed Phase 3 Interventional

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

NCT06058793

View directory record Official record

Conditions: Liposarcoma, Dedifferentiated
Interventions: Brigimadlin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older

Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 21 more

Source: ClinicalTrials.gov public record

Updated Jan 8, 2026 · Synced May 21, 2026, 8:09 PM EDT

Recruiting Phase 1Phase 2 Interventional

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

NCT06239272

View directory record Official record

Conditions: Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma, Myoepithelioma, Fibrosarcoma NOS, Myxofibrosarcoma, Angiosarcoma, Osteosarcoma, Extraskeletal
Interventions: Surgical resection, Proton beam radiation therapy, Pazopanib, Ifosfamide, Doxorubicin, Selinexor; Procedure · Radiation · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 30 Years

Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 6
States / cities: Chicago, Illinois • Baton Rouge, Louisiana • Boston, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated May 18, 2026 · Synced May 21, 2026, 8:09 PM EDT

Recruiting Phase 1Phase 2 Interventional

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

NCT06843967

View directory record Official record

Conditions: Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma, Myxoid Liposarcoma, Round Cell Liposarcoma, Myxoid Pleomorphic Liposarcoma, Pleomorphic Liposarcoma, Unresectable Liposarcoma, Unresectable Dedifferentiated Liposarcoma
Interventions: Mirdametinib, Palbociclib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Source: ClinicalTrials.gov public record

Updated Mar 12, 2026 · Synced May 21, 2026, 8:09 PM EDT